Drug intelligence / Profile preview

M011

Development stage: Preclinical
Modality: Peptides
Administration: Oral

Overview

M011 is a cell-permeable stapled peptide designed to bind with high affinity to Mdm2, a primary antagonist of the p53 tumor suppressor. This binding leads to the activation of p53, making M011 a potential therapeutic agent for cancer. Its structure includes a non-natural L-6-chlorotryptophan residue, which contributes to its improved affinity.

Targets

MDM4 (Mouse double minute X homolog)MDM2 (Mouse double minute 2 homolog)

Beyond the preview

Go deeper on M011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on M011.

Explore the full profile